Ofir Moreno

CVS‐3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts

Anna Galkin, Lynne Mullen, William D. Fox et al. · The Prostate · 2004 · 87 citations

Phase 1, open‐label, dose escalation, safety, and pharmacokinetics study of ME‐344 as a single agent in patients with refractory solid tumors

Johanna C. Bendell, Manish R. Patel, Jeffrey R. Infante et al. · Cancer · 2014 · 30 citations · Full text

Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers

Ofir Moreno, Todd Butler, Vanessa Zann et al. · Clinical Therapeutics · 2018 · 27 citations · Full text

Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models

Ofir Moreno, Jamie Wood · Targeted Oncology · 2019 · 15 citations · Full text

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

Shubham Pant, Howard A. Burris, Kathleen N. Moore et al. · Investigational New Drugs · 2013 · 11 citations · Full text